ManaMed Reports Revolutionary Wearable Ultrasound Device Gains FDA Approval

Manamed, a pioneering Medical Technology development company, has been granted FDA approval on its latest orthopedic recovery device, ManaSport

ManaMed (ManaMed.com) is proud to announce the U.S. Food and Drug Administration (FDA) approval for the ManaSport™ ultrasound therapy Class II device. The ManaSport device, is a new ultrasound therapy device that provides pain relief and treatment for soft-tissue injuries and is popular among athletes and sports professionals. Safe and easy to use, the new device is set to offer life-changing support to those suffering from ongoing issues.

FDA approval has now cleared the product for a range of indications for use, including:

Chronic pain relief.
Muscle spasms and joint contractures.
Relief from pain and joint contractures associated with adhesive capsulitis, bursitis with slight calcification, myositis, soft tissue injuries, and shortened tendons from past injuries and scar tissue.
Relief from pain and muscle spasms resulting from capsular tightness and capsular scarring.
Increasing localized blood flow.
Increasing the range of motion of contracted joints with heat and stretch techniques.

Portable and rechargeable, the device can now be prescribed by medical professionals and is intended for supervised use. It provides non-invasive pulsed ultrasound therapy at localized sites through ultrasound gel, with no discomfort to the patient. A complete therapy session takes just 20 minutes, and the product comes complete with everything you need to carry out therapy sessions, including ultrasound gel, a strap to hold the applicator in place, and a battery charger.

This compact medical device has an intuitive display with simple instructions for use. A built-in calendar helps users stay on top of treatments, while special safety features can lock the device to avoid unintended operation. Physicians and physiotherapists can manually move the applicator throughout the affected area, or use the included strap for a static, hands-free treatment.

Put simply, ManaSport provides a straightforward and effective solution for many medical and sports-related issues and conditions, without the need for surgery or opioids. With the new FDA approval, ManaSport is sure to become the go-to therapy for sports medicine doctors everywhere.

Trevor Theriot, President, and CEO commented, “ManaMed will continue to design, develop, and innovate the entire Med Tech space.  ManaSport demonstrates our commitment to invest in the future and expand our access to the entire continuum of care.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”